Philadelphia, PA, February 13, 2019 - Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer (NSCLC). Assessing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback